Predictive factors of neoadjuvant immune checkpoint blockade in melanoma.
Publication
, Journal Article
Sarver, M; Brown, MC; Rhodin, KE; Salama, AKS; Beasley, GM
Published in: Hum Vaccin Immunother
May 31, 2022
This review describes the current body of literature and ongoing clinical trials examining neoadjuvant immune checkpoint inhibitors (ICI) for patients with resectable stage III and IV melanoma. Based on prior success in treating metastatic melanoma and as adjuvant therapy, ICIs are being explored in the neoadjuvant setting. There have been initial trials and there are many ongoing trials examining neoadjuvant ICI. Herein, we will review the clinical feasibility and efficacy of various neoadjuvant ICI regimens, explore pathologic and cellular responses, and present factors associated with predictive tumor response.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Hum Vaccin Immunother
DOI
EISSN
2164-554X
Publication Date
May 31, 2022
Volume
18
Issue
3
Start / End Page
1943987
Location
United States
Related Subject Headings
- Virology
- Neoadjuvant Therapy
- Melanoma
- Immune Checkpoint Inhibitors
- Humans
- Combined Modality Therapy
- 3207 Medical microbiology
- 3206 Medical biotechnology
- 3204 Immunology
- 1115 Pharmacology and Pharmaceutical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Sarver, M., Brown, M. C., Rhodin, K. E., Salama, A. K. S., & Beasley, G. M. (2022). Predictive factors of neoadjuvant immune checkpoint blockade in melanoma. Hum Vaccin Immunother, 18(3), 1943987. https://doi.org/10.1080/21645515.2021.1943987
Sarver, Melissa, Michael C. Brown, Kristen E. Rhodin, April K. S. Salama, and Georgia M. Beasley. “Predictive factors of neoadjuvant immune checkpoint blockade in melanoma.” Hum Vaccin Immunother 18, no. 3 (May 31, 2022): 1943987. https://doi.org/10.1080/21645515.2021.1943987.
Sarver M, Brown MC, Rhodin KE, Salama AKS, Beasley GM. Predictive factors of neoadjuvant immune checkpoint blockade in melanoma. Hum Vaccin Immunother. 2022 May 31;18(3):1943987.
Sarver, Melissa, et al. “Predictive factors of neoadjuvant immune checkpoint blockade in melanoma.” Hum Vaccin Immunother, vol. 18, no. 3, May 2022, p. 1943987. Pubmed, doi:10.1080/21645515.2021.1943987.
Sarver M, Brown MC, Rhodin KE, Salama AKS, Beasley GM. Predictive factors of neoadjuvant immune checkpoint blockade in melanoma. Hum Vaccin Immunother. 2022 May 31;18(3):1943987.
Published In
Hum Vaccin Immunother
DOI
EISSN
2164-554X
Publication Date
May 31, 2022
Volume
18
Issue
3
Start / End Page
1943987
Location
United States
Related Subject Headings
- Virology
- Neoadjuvant Therapy
- Melanoma
- Immune Checkpoint Inhibitors
- Humans
- Combined Modality Therapy
- 3207 Medical microbiology
- 3206 Medical biotechnology
- 3204 Immunology
- 1115 Pharmacology and Pharmaceutical Sciences